Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Revenue (2016 - 2025)

Altimmune (ALT) has disclosed Revenue for 16 consecutive years, with $26000.0 as the latest value for Q4 2025.

  • Quarterly Revenue rose 420.0% to $26000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41000.0 through Dec 2025, up 105.0% year-over-year, with the annual reading at $41000.0 for FY2025, 105.0% up from the prior year.
  • Revenue for Q4 2025 was $26000.0 at Altimmune, up from $5000.0 in the prior quarter.
  • The five-year high for Revenue was $3.3 million in Q4 2021, with the low at $2000.0 in Q3 2022.
  • Average Revenue over 5 years is $248250.0, with a median of $14500.0 recorded in 2022.
  • The sharpest move saw Revenue tumbled 99.21% in 2022, then surged 18000.0% in 2023.
  • Over 5 years, Revenue stood at $3.3 million in 2021, then crashed by 99.21% to $26000.0 in 2022, then soared by 42.31% to $37000.0 in 2023, then crashed by 86.49% to $5000.0 in 2024, then skyrocketed by 420.0% to $26000.0 in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $26000.0, $5000.0, and $5000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.